Author

A. Garcia-Gimenez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

B. Huntly· 2 shared S. E. Richardson· 2 shared A. Godsinia· 1 shared A. R. Fard· 1 shared C. K. Lopez· 1 shared C. Kapeni· 1 shared C. M. Sauer· 1 shared D. M. A. Azazi· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Huntly

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition

A. Garcia-Gimenez, J. E. Ditcham, D. M. A. Azazi, E. Meduri, R. Asby, N. Sakakini, C. K. Lopez, N. Narayan, T. Beinortas, J. Bagri, S. Agrawal Singh, G. Giotopoulos, M. P. Murphy, S. J. Horton, B. Huntly, S. E. Richardson

This study identifies CREBBP mutations as a targetable vulnerability in B-ALL, showing that CREBBP inhibition sensitizes these cells to Venetoclax-induced ferroptosis.

bioRxiv · Oct 2, 2023 · PreprintCancer Biology

LGR5 targeting molecules as therapeutic agents for multiple cancer types

H.-C. Chen, N. Mueller, K. Stott, E. Rivers, C. Kapeni, C. M. Sauer, F. Beke, S. Walsh, N. Ashman, L. M. O'Brien, A. R. Fard, A. Godsinia, F. Joud, O. Giger, I. Zlobec, , M. de la Roche

This study develops LGR5-targeting antibodies and therapeutics that effectively kill CRC, HCC, and pre-B ALL cancer cells while sparing normal tissues.

bioRxiv · Sep 1, 2022 · PreprintCell Biology